BioCentury
ARTICLE | Finance

BET on the future

Oncoethix seeking POC for BET bromodomain inhibitor with B round money

July 15, 2013 7:00 AM UTC

Oncoethix S.A. plans to use the CHF18 million ($19.1 million) it raised in a series B round last week to demonstrate Phase II proof of concept for its BET bromodomain inhibitor in hematologic and solid cancers.

New investor SV Life Sciences led the round with participation from new investor Edmond de Rothschild Investment Partners along with existing investors Index Ventures and Endeavour Vision...